Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/cen.13346 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment Advances in Tumor-Induced Osteomalacia.
Calcif Tissue Int
January 2025
National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, 20892, USA.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by hypersecretion of fibroblast growth factor 23 (FGF23) by typically benign phosphaturic mesenchymal tumors (PMTs). FGF23 excess causes chronic hypophosphatemia through renal phosphate losses and decreased production of 1,25-dihydroxy-vitamin-D. TIO presents with symptoms of chronic hypophosphatemia including fatigue, bone pain, weakness, and fractures.
View Article and Find Full Text PDFTiming of parathyroidectomy after kidney transplantation: A cost-effectiveness analysis.
Surgery
January 2025
Department of Surgery, Heersink School of Medicine, University of Alabama at Birmingham, AL. Electronic address:
Introduction: Parathyroidectomy is the definitive treatment for tertiary hyperparathyroidism post-kidney transplantation. However, cinacalcet-based medical management is increasingly used as an alternative. The financial consequences of each treatment remain unclear.
View Article and Find Full Text PDFCombination of the CRAC Channel Inhibitor CM4620 and Galactose as a Potential Therapy for Acute Pancreatitis.
Function (Oxf)
July 2024
Cardiff School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3AX, UK.
Article Synopsis
- Acute pancreatitis (AP) is a serious inflammatory condition with no specific treatments available; it's triggered by factors like elevated calcium levels and ATP depletion.
- A new drug, CM4620, currently in Phase 2b trials, shows promise as a CRAC channel inhibitor for AP but requires high concentrations for effectiveness, which could cause side effects.
- Combining lower doses of CM4620 with galactose, a natural carbohydrate, significantly enhances protective effects against cell damage and inflammation in AP models, suggesting a synergistic approach to treatment.
Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore.
Cureus
November 2023
Medicine, Monash University, Melbourne, AUS.
Introduction Chronic kidney disease-related mineral and bone disorder (CKD-MBD), characterized by abnormalities in calcium, phosphate, and parathyroid hormone metabolism, with impaired bone turnover and extravascular calcification is a known complication of advanced chronic kidney disease (CKD). Secondary hyperparathyroidism (SHPT) develops early in the disease and its prevalence gradually increases with the disease progression, becoming almost universal in patients with end-stage renal disease (ESRD). The treatment for SHPT includes synthetic vitamin D analogs, calcitriol or calcimimetics.
View Article and Find Full Text PDFComparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism.
Kidney Int Rep
November 2023
Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
Introduction: Evocalcet is an oral calcimimetic agent with proven efficacy and safety in treating secondary hyperparathyroidism (SHPT) in Japanese patients on dialysis.
Methods: This randomized, double-blind, intrapatient dose-adjustment, parallel-group, international multicenter study compared the efficacy and safety of evocalcet versus cinacalcet for 52 weeks in East Asian hemodialysis patients with SHPT.
Results: In total, 203 and 200 patients were randomized to receive evocalcet or cinacalcet, respectively (overall, 70.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!